Cargando…

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)

Major depressive disorder (MDD) is one of the most prevalent mental illness and a leading cause of disability worldwide. Despite a range of effective treatments, more than 30% of patients do not achieve remission as a result of conventional therapy. In these circumstances the identification of novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosiołek, Anna, Pięta, Aleksandra, Jakima, Sławomir, Zborowska, Natalia, Mosiołek, Jadwiga, Szulc, Agata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071355/ https://www.ncbi.nlm.nih.gov/pubmed/33920992 http://dx.doi.org/10.3390/jcm10081706

Ejemplares similares

Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

The Effects of Treatment in Psychotic Disorders—Changes in BDNF Levels and Clinical Outcomes: Systematic Review
por: Mosiołek, Anna, et al.
Publicado: (2023)

Brain-Derived Neurotrophic Factor (BDNF) as an Indicator for Effects of Cognitive Behavioral Therapy (CBT): A Systematic Review
por: Mosiołek, Anna, et al.
Publicado: (2022)

Cognitive impairment in schizophrenia across age groups: a case–control study
por: Mosiołek, Anna, et al.
Publicado: (2016)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Major depressive disorder (MDD), antidepressants, and uncontrolled hypertension: A report of intraoperative autonomic dysregulation
por: Paraskeva, Anteia, et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on the Use of Antidepressant and Antianxiety Pharmaceuticals as Well as Sick Leave in Poland
por: Krupa, Dominika, et al.
Publicado: (2022)

The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
por: Koopowitz, Sheri‐Michelle, et al.
Publicado: (2021)

The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD)
por: Pieters, T., et al.
Publicado: (2022)

Comparison of Electroencephalography (EEG) Coherence between Major Depressive Disorder (MDD) without Comorbidity and MDD Comorbid with Internet Gaming Disorder
por: Youh, Joohyung, et al.
Publicado: (2017)

Factors Related to the Level of Depression and Suicidal Behavior Among Men With Diagnosed Depression, Physically Ill Men, and Healthy Men
por: Kielan, Aleksandra, et al.
Publicado: (2021)

The process of major depressive disorder (MDD) in women referred to the health centers
por: Rahmati-Khameneh, Souraj, et al.
Publicado: (2011)

Major depressive disorder (MDD) in adolescents with Borderline (BPD) and Shyzotypal personality disorder (STPD)
por: Kaleda, V., et al.
Publicado: (2023)

The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
por: Proudman, David, et al.
Publicado: (2021)

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
por: Keyloun, Katelyn R., et al.
Publicado: (2017)

Differential malondialdehyde (MDA) detection in plasma samples of patients with major depressive disorder (MDD): A potential biomarker
por: Alvarez-Mon, Miguel A, et al.
Publicado: (2022)

Clinical evaluation of Major Depressive Disorder (MDD) and Borderline Personality Disorder(BPD) in youth adolescents
por: Kaleda, V., et al.
Publicado: (2022)

Skin conductance responses in Major Depressive Disorder (MDD) under mental arithmetic stress
por: Kim, Ah Young, et al.
Publicado: (2019)

S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review
por: Cuomo, Alessandro, et al.
Publicado: (2020)

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects
por: Alvarez-Mon, Miguel A., et al.
Publicado: (2021)

The Potential Biomarker Panels for Identification of Major Depressive Disorder (MDD) Patients with and without Early Life Stress (ELS) by Metabonomic Analysis
por: Ding, Xinghua, et al.
Publicado: (2014)

The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
por: Waters, Kristin
Publicado: (2022)

PHQ-8 Days: a measurement option for DSM-5 Major Depressive Disorder (MDD) severity
por: Dhingra, Satvinder S, et al.
Publicado: (2011)

MK4MDD: A Multi-Level Knowledge Base and Analysis Platform for Major Depressive Disorder
por: Guo, Liyuan, et al.
Publicado: (2012)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)
por: Yang, Kai, et al.
Publicado: (2019)

Health behaviors and problems in Polish homeless men
por: Repka, Bernadetta, et al.
Publicado: (2023)

Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review
por: Zelada, Mario Ignacio, et al.
Publicado: (2023)

Oxidative Stress Biomarkers among Schizophrenia Inpatients
por: Więdłocha, Magdalena, et al.
Publicado: (2023)

Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis
por: Rao, Shuquan, et al.
Publicado: (2016)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

A survey of five antidepressant properties influencing clinician’s treatment choices in MDD
por: Papakostas, George I, et al.
Publicado: (2007)

White matter integrity and pro-inflammatory cytokines as predictors of antidepressant response in MDD
por: Breit, S., et al.
Publicado: (2022)

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder
por: Song, Ruize, et al.
Publicado: (2021)

Potential of antithrombin III as a biomarker of antidepressive effect in major depressive disorder
por: Song, R., et al.
Publicado: (2021)

Should antidepressants be used for major depressive disorder?
por: Jakobsen, Janus Christian, et al.
Publicado: (2020)

A Novel Peripheral Biomarker for Depression and Antidepressant Response
por: Targum, Steven D., et al.
Publicado: (2022)

Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials
por: Vida, Róbert György, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m7t7gi9ilf5ehnn73abj8oosid